Delcath Systems, Inc. 2014 Form 10-K Summary
Business context and reporting period
Delcath is a late-stage clinical development and specialty pharmaceutical/medical-device company focused on liver cancers. Its primary product is Melphalan/HDS, marketed in Europe as the CE-marked Class IIb medical device CHEMOSAT. The filing covers the fiscal year ended December 31, 2014; fourth-quarter information is presented only through selected unaudited quarterly data.
CHEMOSAT had early commercial activity in Europe, while Melphalan/HDS was not approved for sale in the United States. The company was conducting or planning clinical programs in ocular melanoma liver metastases, hepatocellular carcinoma and intrahepatic cholangiocarcinoma.
Financial performance and liquidity
| Metric | FY2014 | FY2013 | Change |
|---|---|---|---|
| Total revenue | $1.069 million | $0.790 million | 35.3% increase |
| Gross profit | $0.778 million | $0.326 million | 139% increase |
| Gross margin | 72.8% | 41.3% | Improved |
| Operating loss | $19.304 million | $33.019 million | 41.5% reduction |
| Net loss | $17.381 million | $30.324 million | 42.6% reduction |
| Basic loss per share | $1.84 | $4.81 | Improved |
| Cash used in operations | $15.552 million | $34.102 million | Reduced by $18.550 million |
| Cash and cash equivalents at year-end | $20.469 million | $31.249 million | 34.5% decrease |
Revenue consisted primarily of CHEMOSAT product sales. Cost of goods sold was $0.291 million, producing $0.778 million of gross profit. Selling, general and administrative expense was $15.783 million, and research and development expense was $4.299 million. The filing does not provide a clear fourth-quarter revenue value in the selected quarterly data, but fourth-quarter net loss was $2.945 million and operating loss was $3.285 million.
Total assets were $23.764 million, current assets were $21.966 million and current liabilities were $4.576 million at December 31, 2014. Stockholders’ equity was $18.145 million. The company had no borrowings outstanding under its $20 million revolving credit facility with Silicon Valley Bank, subject to borrowing-base and cash requirements. Operating lease obligations totaled approximately $2.2 million in the MD&A contractual-obligations table, while the notes list future minimum lease payments of approximately $2.046 million; investors should reconcile the presentation differences.
Management stated that available capital was expected to fund operating activities into the first half of 2016, but also stated that additional working capital would be required and that continued losses could exhaust capital resources.
Material changes versus the prior comparable period
- Revenue increased by $0.279 million, primarily from greater European commercial activity. CHEMOSAT treatments performed in Europe increased to 79 in 2014, including 34 retreatments, versus 2013 levels described as approximately half as high for total treatments and substantially lower for retreatments.
- Operating expenses declined by $13.263 million, reflecting workforce reductions, lower compensation and severance expense, and sharply lower NDA-related regulatory and clinical spending.
- The company reduced its workforce by more than 30% during 2014, ending the year with 25 full-time employees compared with 37 at December 31, 2013.
- Research and development expense declined from $12.688 million to $4.299 million, while SG&A declined from $20.657 million to $15.783 million.
- Cash declined by $10.780 million during 2014 despite $4.869 million of net equity and warrant-exercise proceeds, primarily because operating cash use remained significant.
- A $1.942 million gain from the change in fair value of warrant liabilities reduced the reported net loss but was non-cash and subject to valuation volatility.
- The company recorded approximately $1.3 million of 2014 restructuring and lease-related costs, including costs associated with vacating and subleasing office space.
- A one-for-sixteen reverse stock split became effective in April 2014. Share counts, share prices and per-share data were retrospectively adjusted.
Guidance, outlook, risks and unusual items
The company planned to advance a pivotal global Phase 3 overall-survival trial in ocular melanoma liver metastases and continue Phase 2 HCC programs in the United States and Europe. It expected to add an ICC cohort in 2015. U.S. Protocol 201 opened enrollment in October 2014, and three German hospitals had opened enrollment under the European protocol.
The FDA issued a Complete Response Letter in September 2013 for the company’s Melblez Kit NDA. The FDA required additional well-controlled randomized trials using overall survival as the primary efficacy endpoint, conducted with the product intended for marketing, along with additional product-quality and human-factors work. U.S. approval therefore remained uncertain and no U.S. product revenue was expected in the near term.
European commercialization depended heavily on reimbursement. Germany continued to provide Value 4 NUB status, which permits negotiated reimbursement but does not mandate coverage. German Individual Funding Requests were an important reimbursement mechanism. In the United Kingdom, potential Commissioning Through Evaluation funding was delayed and uncertain, while NICE recommended that the procedure be performed in a research context because available safety and efficacy evidence was limited.
Key risks include continued operating losses and negative operating cash flow; the need for additional capital; clinical-trial failure or delay; FDA or foreign regulatory non-approval; significant procedure-related toxicity; uncertain reimbursement; limited commercialization experience; dependence on third-party manufacturers and sole-source suppliers; availability of melphalan in Europe; intellectual-property expiration and trade-secret risks; product-liability exposure; securities and derivative litigation; and potential equity dilution.
Material subsequent events included a February 2015 offering of approximately 2.46 million common shares and warrants for approximately 1.107 million shares, generating approximately $2.4 million of net proceeds. The offering also adjusted the exercise price of the 2012 warrants to $0.82. The company stated that its Form S-3 and at-the-market financing capacity was constrained by applicable public-float limits.
Outstanding legal matters included a purported securities class action and several shareholder derivative actions relating primarily to disclosures concerning the Melblez Kit NDA and manufacturing facilities. The company and individual defendants denied wrongdoing and intended to defend the matters vigorously.
Most important facts for investors to verify
- Whether cash resources and the February 2015 financing are sufficient to fund planned clinical trials and operations, given continuing losses and the stated need for additional capital.
- The status, design, enrollment and cost of the planned ocular melanoma Phase 3 trial and the requirements remaining under the FDA Complete Response Letter.
- Whether Phase 2 HCC and future ICC data demonstrate clinically meaningful efficacy with an acceptable safety profile.
- The sustainability of European CHEMOSAT utilization, pricing, gross margin and reimbursement, particularly in Germany and the United Kingdom.
- The effect of the February 2015 share and warrant issuance, future financing restrictions and potential dilution.
- The potential financial exposure and status of the securities class action, derivative actions and other contingencies.
- The reliability of management’s cash-runway estimate, including differences between the filing’s statements regarding funding through 2015 and into the first half of 2016.